A short cycle of narrow-band UVB phototherapy in the early phase of long-term efalizumab can provide a quicker remission of moderate and severe psoriasis: A pilot study

Dermatology

Volumn 218, Issue 4, 2009, Pages 321-326

  Zane, Cristina ^a   Capezzera, Rossana ^a   Venturini, Marina ^a   Sala, Raffaella ^a   Facchinetti, Elena ^a   Pedretti, Alessandra ^a   Calzavara Pinton, Piergiacomo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Efalizumab; Narrow band ultraviolet B phototherapy; Psoriasis, remission

Indexed keywords

EFALIZUMAB;

ABSENCE OF SIDE EFFECTS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HUMAN; MALE; MONOTHERAPY; PHOTOTHERAPY; PILOT STUDY; PRIORITY JOURNAL; PSORIASIS; ULTRAVIOLET B RADIATION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIGENS, CD11; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; PILOT PROJECTS; PSORIASIS; ULTRAVIOLET THERAPY;

EID: 67651108960     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000204715     Document Type: Article

References (31)

1. Papp KA: The long-term efficacy and safety of new biological therapies for psoriasis. Arch Dermatol Res 2006; 298: 7-15.
2. Weischer M, Blum A, Eberhard F, Röcken M, Berneburg M: No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004; 84: 370-374. (Pubitemid 39312270)
3. Carrascosa JM, Soria X, Ferrandiz C: Effective management of a psoriatic flare with narrowband UVB phototherapy during efalizumab therapy without discontinuing treatment. J Eur Acad Dermatol Venereol 2007; 21: 828-829. (Pubitemid 46939062)
4. Wainwright NJ, Dawe RS, Ferguson J: Narrowband ultraviolet B (TL-01) phototherapy for psoriasis: which incremental regimen? Br J Dermatol 1998; 139: 410-414.
5. Fredriksson T, Pettersson U: Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157: 238-244. (Pubitemid 8387357)
6. Tzaneva S, Honigsmann H, Tanew A: Observer-blind randomized, intrapatient comparison of a novel 1% coal tar preparation (Exorex) and calcipotriol cream in the treatment of plaque type psoriasis. Br J Dermatol 2003; 149: 350-353. (Pubitemid 37107339)
7. Krueger JG: The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1-23. (Pubitemid 34073472)
8. Cather JC, Menter A: Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin Biol Ther 2003; 3: 361-370.
9. Ozawa M, Ferenczi K, Kikuchi T, Cardinale I, Austin LM, Coven TR, Burack LH, Krueger JG: 312-nanometer ultraviolet B (narrowband UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999; 189: 711-718. (Pubitemid 29193372)
10. Barr RM, Walker SL, Tsang W, Harrison GI, Ettehadi P, Greaves MW, Young AR: Suppressed alloantigen presentation, increased TNF-alpha, IL-1, IL-1Ra, IL-10, and modulation of TNF-R in UV-irradiated human skin. J Invest Dermatol 1999; 112: 692-698. (Pubitemid 29220709)
11. Sigmundsdottir H, Johnston A, Gudjonsson JE, Valdimarsson H: Narrowband-UVB irradiation decreases the production of proinflammatory cytokines by stimulated T cells. Arch Dermatol Res 2005; 297: 39-42. (Pubitemid 41380681)
12. Duthie MS, Kimber I, Norval M: The effects of ultraviolet radiation on the human immune system. Br J Dermatol 1999; 140: 995-1009. (Pubitemid 29284569)
13. Norval M, Gibbs NK, Gilmour J: The role of urocanic acid in UV-induced immunosuppression: recent advances (1992-1994). Photochem Photobiol 1995; 62: 209-217.
14. Menter A, Gordon K, Carey W, Hamilton T, Glazer S, Caro I, Li N, Gulliver W: Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis. Arch Dermatol 2005; 141: 31-38. (Pubitemid 40144437)
15. Ortonne JP, Shear N, Shumack S, Henninger E, CLEAR Multinational Study Group: Impact of efalizumab on patient-reported outcomes in high-need psoriasis patients: results of the international, randomized, placebo-controlled phase III Clinical Experience Acquired with Raptiva (CLEAR) trial. BMC Dermatol 2005; 5: 13. (Pubitemid 43013367)
16. Dubertret L, Sterry W, Bos JD, Chimenti S, Shumack S, Larsen CG, Shear NH, Papp KA, CLEAR Multinational Study Group: Clinical experience acquired with efalizumab (Raptiva) (CLEAR) trial in patients with moderate- to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial. Br J Dermatol 2006; 155: 170-181. (Pubitemid 43876411)
17. Costanzo A, Peris K, Talamonti M, Di Cesare A, Fargnoli MC, Botti E, Chimenti S: Longterm treatment of plaque psoriasis with efalizumab: an Italian experience. Br J Dermatol 2007; 156(suppl 2):17-23. (Pubitemid 46434870)
18. Poulin Y, Papp KA, Carey W, Gulliver W, Gupta AK: A favourable benefit/risk ratio with efalizumab: a review of the clinical evidence. J Cutan Med Surg 2006; 9(suppl 1):10-17. (Pubitemid 44244080)
19. Pariser DM, Gordon KB, Papp KA, Leonardi CL, Kwon P, Compton PG, Rundle AC, Walicke PA, Lebwohl M: Clinical efficacy of efalizumab in patients with chronic plaque psoriasis: results from three randomized placebo-controlled phase III trials. Part I. J Cutan Med Surg 2005; 9: 303-312. (Pubitemid 44491080)
20. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB, Efalizumab Study Group: Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol 2005: 52: 425-433.
21. Leonardi CL, Powers JL, Matheson RT, Goffe BS, Zitnik R, Wang A, Gottlieb AB, Etanercept Psoriasis Study Group: Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349: 2014-2022.
22. Saurat JH, Stingl G, Dubertret L, Papp K, Langley RG, Ortonne JP, Unnebrink K, Kaul M, Camez A: Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008; 158: 558-566. (Pubitemid 351239154)
23. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, Li S, Dooley LT, Griffiths CE, EXPRESS study investigators: Infliximab induction and maintenance therapy for moderate to severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005; 366: 1367-1374. (Pubitemid 41443403)
24. Gisondi P, Girolomoni G: Combination of efalizumab and acitretin in chronic plaque psoriasis. J Eur Acad Derm Venereol 2008; 22: 247-248.
25. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology 2006; 213: 204-214. (Pubitemid 44567830)
26. Ortonne JP, Khemis A, Koo JY, Choi J: An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. J Eur Acad Derm Venereol 2005; 19: 556-563. (Pubitemid 41742835)
27. Scheinfeld N: Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. Dermatol Online J 2005; 11: 7.
28. Legat FJ, Hofer A, Wackernagel A, Salmhofer W, Quehenberger F, Kerl H, Wolf P: Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. Arch Dermatol 2007; 143: 1016-1022. (Pubitemid 47296078)
29. Brunasso AMG, Delfino C, Massone C: Efalizumab rebound response to a sequential therapy of infliximab followed by efalizumab. Dermatology 2009;218:73-74.
30. Barde C, Thielen AM, Saurat JH: Infliximab, then efalizumab: the 'hit and run' approach does not work. Dermatology 2008; 216: 171-172.
31. Costanzo A, Talamonti M, Spallone G, Botti E, Chimenti MS, Papoutsaki M, Chimenti S: Efficacy of short-term cyclosporine treatment to control psoriasis-related events during efalizumab therapy. Dermatology 2009;218:146-150.